Investment Rating - The investment rating for the company is "Buy" [13] Core Insights - The report highlights Haiguang Information as a leading domestic high-end CPU and DCU enterprise, benefiting from the deepening of domestic innovation and the AI era, with significant growth expected in both CPU and DCU businesses [4][8][10]. Summary by Sections Company Overview - Haiguang Information, established in 2014, focuses on the research, design, and sale of high-end processors used in servers and workstations, with main products including Haiguang general processors (CPU) and deep computing units (DCU) [8][22]. Financial Performance - The company has shown rapid revenue growth, with projected revenues of 9.162 billion yuan for 2024 and 9.490 billion yuan for the first three quarters of 2025, representing year-on-year growth of 52.4% and 54.65% respectively. The net profit attributable to shareholders is expected to reach 1.931 billion yuan and 1.961 billion yuan for the same periods, with growth rates of 52.87% and 28.56% respectively [8][39]. Market Dynamics - The report indicates that the market for high-performance processors is expanding, with the Chinese CPU market expected to grow to 232.61 billion yuan in 2024, reflecting a year-on-year increase of 7.7%. The demand for high-performance, low-power, and highly integrated processors is increasing across various sectors [9][53][55]. Competitive Advantages - Haiguang Information is positioned in the first tier of domestic CPU manufacturers, benefiting from its compatibility with the x86 ecosystem, performance advantages, and security features. The company is expected to maximize its benefits from the ongoing domestic innovation push [9][10]. AI and DCU Growth - The AI era is driving a surge in demand for computing power, with the domestic AI chip market projected to grow from 11.6 billion yuan in 2019 to 141.2 billion yuan in 2024, reflecting a compound annual growth rate of 64.84%. Haiguang's DCU products are expected to see significant growth due to their continuous upgrades and compatibility with "CUDA-like" environments [10][11]. Strategic Moves - The company plans to absorb and merge with Zhongke Shuguang, which will enhance its capabilities from core AI chips to full-stack solutions, aiming to create a new ecosystem for domestic computing power through an "AI computing open architecture" [11][30].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [12][14]. Core Insights - The company, Genting Biopharma, focuses on innovative drug and vaccine research, manufacturing, and commercialization, establishing a dual-driven growth model through license-in products and self-developed high-barrier pipelines [3][8]. - Key products include Nefukang (Budesonide) for IgA nephropathy, EVER001 for primary membranous nephropathy, and Aicuo Mod (Etrolizumab) for moderate to severe ulcerative colitis, all showing significant clinical evidence and market potential [9][10][11]. - The company has seen substantial revenue growth, with projected revenues of 1.791 billion, 3.169 billion, and 4.822 billion RMB for 2025-2027, respectively, and a turnaround in profitability expected by 2025 [12][30]. Summary by Sections Company Overview - Genting Biopharma was founded in July 2017 and has developed a diverse product pipeline covering oncology, nephrology, and infectious diseases [18]. - The company has shifted focus towards nephrology and autoimmune diseases, divesting from oncology to enhance resource allocation [18]. Product Pipeline - The product pipeline includes Nefukang, which is the first approved drug for IgA nephropathy globally, and EVER001, a reversible BTK inhibitor targeting primary membranous nephropathy [9][10]. - Aicuo Mod has shown rapid efficacy in inducing clinical remission in ulcerative colitis patients, with a significant mucosal healing rate [11]. Financial Performance - The company achieved a revenue of 707 million RMB in 2024, a 461% increase year-on-year, and expects continued growth with a revenue of 446 million RMB in the first half of 2025 [28][30]. - The net profit is projected to improve from a loss of 376 million RMB in 2025 to a profit of 868 million RMB by 2027, indicating a strong recovery trajectory [12][30]. Market Potential - The chronic kidney disease (CKD) patient population is substantial, with approximately 1.25 billion patients in China, representing a significant market opportunity for the company's nephrology products [32]. - The company’s products are positioned to address unmet medical needs in the nephrology and autoimmune disease sectors, with a focus on innovative treatment approaches [3][8].

- The report highlights the performance of the A-share market, with the CSI A50 leading the gains and the ChiNext Index showing strong performance[1][6] - The Dividend Enhanced Portfolio outperformed the CSI Dividend Total Return Index, with the Central SOE High Dividend 30 Portfolio and the Balanced Dividend 50 Portfolio achieving weekly excess returns of approximately 0.41% and 0.75%, respectively[6][21] - The Electronic Enhanced Portfolio also outperformed the Electronic Total Return Index, with the Electronic Balanced Allocation Enhanced Portfolio and the Electronic Sector Preferred Enhanced Portfolio achieving weekly excess returns of approximately 1.78% and 1.53%, respectively[6][29]

Export Performance - November exports increased by 5.9% year-on-year, exceeding the expected 3.8%[6] - Monthly export value reached $330.35 billion, with imports at $218.67 billion, resulting in a trade surplus of $111.68 billion[6] - Exports to the EU, Africa, and Latin America showed strong growth, with EU exports rising 14.8% year-on-year[6] Trade Dynamics - Exports to the US decreased slightly, with November exports valued at $33.79 billion, a year-on-year decline of 28.6%[6] - Exports to Africa surged by 27.6% year-on-year, with a monthly export value of $20.9 billion[6] - Exports to Latin America also strengthened, with a year-on-year increase of 14.9% and a monthly export value of $26.23 billion[6] Product Categories - High-tech products, electromechanical products, and labor-intensive products saw year-on-year growth rates of 7.7%, 9.7%, and -8.3%, respectively[6] - Integrated circuits and general machinery exports performed strongly, contributing significantly to overall export growth[6] Import Trends - November imports increased by 1.9% year-on-year, below the expected 3%[6] - Major imports included computers and integrated circuits, which showed significant growth in import value[6] Future Outlook - Short-term export pressures are anticipated due to declining container booking volumes since November 9, indicating potential challenges in December[6] - Long-term resilience is expected to be supported by global manufacturing recovery and price advantages of Chinese export goods[6] Risk Factors - Uncertainties surrounding US tariff policies may impact China's export performance, with potential legal challenges affecting future tariff implementations[8]

Report Industry Investment Rating - Not provided in the given content Core Viewpoints - The current "shortening receipt and lengthening issuance" by the central bank does not necessarily mean an increase in liability costs. The central bank's "shortening receipt and lengthening issuance" in terms of quantity is more significant, and the large - scale long - end issuance is more effective in alleviating the liability pressure of financial institutions, especially banks [7]. Summary by Directory 1. Funds - In December 2025, the central bank conducted a 3 - month buy - out reverse repurchase operation of 100 billion yuan at the same volume. From December 1st - 5th, the central bank's 7 - day reverse repurchase had a net withdrawal of 84.8 billion yuan, and from December 8th - 12th, 66.38 billion yuan of 7 - day reverse repurchases will mature. In November, the central bank's net purchase of treasury bonds was 5 billion yuan [6]. - From December 1st - 5th, the average values of DR001 and R001 were 1.30% and 1.36% respectively, down 1.2 basis points and 2.3 basis points compared with November 24th - 28th. The average values of DR007 and R007 were 1.44% and 1.49% respectively, down 1.9 basis points and 3.9 basis points compared with November 24th - 28th [6]. - From December 1st - 7th, the net government bond payment was about 18.66 billion yuan, about 14.23 billion yuan less than November 24th - 30th. From December 8th - 14th, the net government bond payment is expected to be - 79.52 billion yuan [7]. 2. Negotiable Certificates of Deposit (NCDs) - As of December 5th, 2025, the maturity yields of 1 - month and 3 - month NCDs were 1.5793% and 1.6150% respectively, up 13.4 basis points and 4.0 basis points compared with November 28th. The 1 - year NCD maturity yield was 1.6550%, up 1.5 basis points compared with November 28th [8]. - From December 1st - 7th, the net financing of NCDs was about 4.71 billion yuan. From December 8th - 14th, the expected maturity repayment amount of NCDs is 106.24 billion yuan, with a significant increase in the pressure of maturity renewal [8]. 3. Institutional Behavior - From December 1st - 5th, the average leverage ratio of the inter - bank bond market was 107.56%, up from 107.32% in November 24th - 28th [9]. - On December 5th, 2025, the median duration of medium - long - term interest - rate style pure bond funds (MA5) was 4.47 years, a weekly increase of 0.79 years, at the 84.1% quantile since early 2022. The median duration of short - term interest - rate style pure bond funds (MA5) was 1.80 years, a weekly increase of 0.24 years, at the 51.2% quantile since early 2022 [9].

Investment Rating - The report maintains a "Positive" investment rating for the industry [3]. Core Insights - The report highlights the cyclical nature of the lithium battery industry, emphasizing the price and stock performance trends during the last lithium cycle [8]. - It notes that the price of lithium carbonate and other materials has shown significant fluctuations, impacting the profitability of companies within the supply chain [12][19][23]. - The report indicates that the stock prices of major lithium battery companies peaked in late 2021, with a notable lag behind the price peaks of raw materials [39]. Summary by Sections Section 1: Market Review - The previous lithium cycle saw a dramatic increase in prices, with 6F prices rising from 70,000 CNY/ton in mid-2020 to 425,000 CNY/ton by August 2021, while lithium carbonate prices surged to 500,000 CNY/ton by early 2022 [12]. - The report discusses the impact of long-term contracts on pricing stability, noting that leading companies maintained higher prices even as market prices began to decline [12]. Section 2: Price Trends of Key Materials - Iron lithium processing fees increased significantly from Q1 2021 to Q1 2022, with a total rise of approximately 20,000 CNY/ton, before stabilizing and then declining in 2023 [19]. - The report details the price trends of negative electrode materials, indicating a price increase of 10,000 CNY/ton from H2 2021 to Q1 2022 due to supply constraints [23]. - Wet-process separator prices saw a modest increase of 0.2-0.3 CNY/sq.m from H2 2021 to H1 2022, with a subsequent decline starting in Q1 2023 [26]. Section 3: Battery Cost and Profitability - The report estimates that the costs for iron lithium and ternary batteries were 0.77 and 0.91 CNY/Wh respectively in Q2 2022, reflecting an increase from Q1 2021 [31]. - It notes that battery companies were able to pass on cost increases to automakers starting in Q2 2022, leading to stable unit profitability despite earlier cost pressures [31]. Section 4: Stock Performance Review - The report provides a detailed review of stock performance across key companies in the lithium battery sector from 2019 to 2022, highlighting significant gains during the electric vehicle boom [37]. - It notes that the stock prices of most companies peaked in November 2021, with a subsequent decline observed in the following year [39]. - The report emphasizes that the price peaks of raw materials often lagged behind stock price peaks, indicating a complex relationship between market dynamics and stock performance [39].

Investment Rating - The industry investment rating is "Positive" and maintained [11] Core Insights - The financing ecosystem for China's biopharmaceutical industry is gradually entering a positive cycle, driven by the influx of funds from A/H listings and capital increases of innovative drug companies, leading to an improvement in R&D investment sentiment [2][42] - The IPO channels for innovative drugs have widened, with a resurgence in Hong Kong IPOs and improved fundraising conditions for A-share companies, indicating a positive trend in fundraising for R&D investments [6][31] - The amount of biopharmaceutical financing in China is showing signs of recovery, with significant policy support and an increase in investment funds, suggesting a rebound in the financing environment [8][37] Summary by Sections Innovative Drug R&D Investment Sentiment - The trend of key forward-looking indicators suggests that the funding situation for innovative drug companies is becoming more favorable, which is expected to enhance their willingness to invest in R&D [24] - The innovative drug IPO market is experiencing a resurgence, with 17 companies listed in Hong Kong by the end of November 2025, surpassing the total for 2020 [25][27] Fundraising and Financing Trends - The scale of fundraising through IPOs for pharmaceutical companies in Hong Kong has shown significant improvement since April 2025, with notable monthly highs in fundraising amounts [31] - The scale of capital increases for A-share pharmaceutical companies has also been on the rise, with a peak of 3.9 billion yuan in Q3 2025, the highest since Q2 2023 [33] Biopharmaceutical Financing Environment - The total financing amount for China's biopharmaceutical sector reached 1.76 billion USD in Q3 2025, the highest since Q4 2022, indicating a potential bottoming out and recovery in the financing landscape [37] - The amount of upfront payments for external business development (BD) has become a significant source of funding for R&D, with Q3 2025 figures reaching 1.85 billion USD, surpassing the total financing amount for the same period [40]

丨证券研究报告丨 报告要点 [Table_Summary] 12 月 1 日，豆包手机助手以技术预览版正式亮相，搭载该功能的努比亚（nubia）M153 工程 样机同步开售。当前时点，以字节为代表的国产大模型企业，正持续布局手机、耳机等端侧流 量入口，希望通过将大模型能力、超级 App 与硬件终端结合，推动 AI 时代的交互模式变革。 在此背景下，我们认为端侧 AI 或将成为 AI 在日常使用中重要的落地场景，推动 AI Agents 能 力持续提升，进而加速国产 AI 的商业化。建议关注：1）国产大模型厂商；2）AI Infra：AI Infra 有望核心受益；3）AI Agent 相关厂商；4）中国推理算力产业链。 分析师及联系人 [Table_Author] 宗建树 陈耀文 SAC：S0490520030004 SAC：S0490525070002 SFC：BUX668 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 行业研究丨点评报告丨软件与服务 [Table_Title] 豆包手机助手发布，关注端侧 AI 产业进展 软件与服务 cjzqdt11111 ...

Investment Rating - The report maintains a "Positive" investment rating for the non-bank financial sector [7]. Core Insights - The non-bank financial sector has shown strong overall performance this week, with brokerages expected to maintain high growth trends in 2025. The report suggests focusing on the sector's future allocation value [2][4]. - The China Banking and Insurance Regulatory Commission (CBIRC) has issued a notice adjusting risk factors related to insurance companies' business, which is expected to enhance the certainty of ROE improvement and accelerate valuation recovery in the medium to long term [4][6]. - The report recommends companies with stable profit growth and dividend rates, including Jiangsu Jinzu, China Ping An, and China Pacific Insurance, as well as those with significant advantages in business models and market positions [4]. Market Performance - The non-bank financial index increased by 2.3% this week, outperforming the CSI 300 by 1.0%. Year-to-date, the non-bank financial index is up 5.9%, but underperformed the CSI 300 by 10.6% [5][17]. - The average daily trading volume in the market decreased to 16,961.78 billion yuan, down 2.35% week-on-week, while the margin financing balance rose to 2.48 trillion yuan, up 0.48% [5][39]. Key Industry News & Company Announcements - The CBIRC has adjusted risk factors for insurance companies, which is expected to support the growth of patient capital and enhance service quality to the real economy [6][64]. - Companies such as Zhongtai Securities and New China Life have announced their respective stock issuance and dividend distribution plans for the first half of 2025 [6].

Investment Rating - The report maintains a "Positive" investment rating for the banking sector [10] Core Insights - The banking sector has experienced a third consecutive week of decline, primarily due to a rebound in market risk appetite, leading to the outflow of previously defensive capital. The bond market has also adjusted, affecting investment returns. Despite short-term style changes, the report remains optimistic about the revaluation direction of bank stocks, particularly favoring large banks like Bank of Communications and China Merchants Bank, as well as leading city commercial banks such as Nanjing Bank, Jiangsu Bank, and Hangzhou Bank [2][7] - Recent adjustments in insurance risk factors encourage long-term allocations towards low volatility dividend stocks and technology innovation sectors. The National Financial Regulatory Administration has lowered risk factors for certain indices, which is expected to enhance the solvency of insurance companies and promote long-term investments in quality equity assets [4][39] Summary by Sections Market Performance - The banking index fell by 1.1% this week, underperforming the CSI 300 and ChiNext indices by 2.3% and 2.9% respectively. The average dividend yield for the six major state-owned banks in A-shares rose to 3.85%, with a 200 basis point spread over the 10-year government bond yield. H-shares maintain a 5% average dividend yield, with a 23% discount compared to A-shares [7][20][26] Credit Growth - As of the end of October 2025, credit growth across various regions remains differentiated, with major provinces like Jiangsu, Zhejiang, Shandong, Sichuan, and Anhui maintaining growth rates above 8%. Sichuan leads with a growth rate of 10.8%. Corporate loans continue to be the main growth driver, with Jiangsu and Sichuan showing growth rates of 13.6% and 13.3% respectively [6][34] Insurance Capital Allocation - Insurance capital is in a continuous process of increasing allocations to bank stocks, particularly during the third quarter adjustment period. The report outlines three core strategies for capital allocation: large insurance funds strategically investing in state-owned banks and leading city commercial banks, and smaller insurance companies seeking long-term equity investment opportunities in smaller banks [5][39]